Despite advancements, several challenges persist. Tumor heterogeneity and drug resistance are significant hurdles. The genetic diversity within tumors can lead to subpopulations of cells that resist treatment, causing relapse. Additionally, the high cost of novel therapies can limit accessibility, and managing side effects remains a critical aspect of patient care.